FDA approves Nesina,Oseni and Kazano (Takeda) treatments for Type 2 Diabetes
Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced that the FDA has approved Nesina (alogliptin) and the fixed-dose combination (FDC) therapies Oseni (alogliptin and pioglitazone) and Kazano(alogliptin and metformin HCl) for the treatment of Type 2 Diabetes in adults as adjuncts to diet and exercise.
Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). Oseni, which combines alogliptin with pioglitazone, is the first product in the U.S. to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. Kazano combines alogliptin with metformin HCl, a widely used anti-diabetes medication, in a single tablet.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins